T-cell function in chronic lymphocytic leukaemia

Seminars in Cancer Biology

Volumn 20, Issue 6, 2010, Pages 431-438

  Riches, John C ^a   Ramsay, Alan G ^a   Gribben, John G ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antigen presentation; Chronic lymphocytic leukaemia; Lenalidomide; T cell function; Tumour antigens

Indexed keywords

ALEMTUZUMAB; CANCER VACCINE; CD3 ANTIGEN; CD4 ANTIGEN; CD40 LIGAND; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; FLUDARABINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 6; LENALIDOMIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RITUXIMAB; T LYMPHOCYTE RECEPTOR; THALIDOMIDE; TUMOR CELL VACCINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CANCER CELL; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOSURVEILLANCE; LEUKEMOGENESIS; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFER; LYMPHOCYTOPENIA; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANTIGEN-PRESENTING CELLS; CANCER VACCINES; CYTOKINES; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; T-LYMPHOCYTES;

EID: 78649777544     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2010.09.006     Document Type: Review

References (109)

1. Chiorazzi N., Rai K.R., Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005, 352:804-815.
2. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998.
3. Janeway C.A., Ron J., Katz M.E. The B cell is the initiating antigen-presenting cell in peripheral lymph nodes. J Immunol 1987, 138:1051-1055.
4. Noelle R.J., Roy M., Shepherd D.M., Stamenkovic I., Ledbetter J.A., Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci USA 1992, 89:6550-6554.
5. Ranheim E.A., Kipps T.J. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993, 177:925-935.
6. Yellin M.J., Sinning J., Covey L.R., Sherman W., Lee J.J., Glickman-Nir E., et al. T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J Immunol 1994, 153:666-674.
7. Dazzi F., D'Andrea E., Biasi G., De Silvestro G., Gaidano G., Schena M., et al. Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens. Clin Immunol Immunopathol 1995, 75:26-32.
8. Van den Hove L.E., Van Gool S.W., Vandenberghe P., Bakkus M., Thielemans K., Boogaerts M.A., et al. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia 1997, 11:572-580.
9. Cantwell M., Hua T., Pappas J., Kipps T.J. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med 1997, 3:984-989.
10. Kato K., Cantwell M.J., Sharma S., Kipps T.J. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 1998, 101:1133-1141.
11. Takahashi S., Rousseau R.F., Yotnda P., Mei Z., Dotti G., Rill D., et al. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum Gene Ther 2001, 12:659-670.
12. Buhmann R., Nolte A., Westhaus D., Emmerich B., Hallek M. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood 1999, 93:1992-2002.
13. Krackhardt A.M., Harig S., Witzens M., Broderick R., Barrett P., Gribben J.G. T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy. Blood 2002, 100:167-173.
14. Krackhardt A.M., Witzens M., Harig S., Hodi F.S., Zauls A.J., Chessia M., et al. Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 2002, 100:2123-2131.
15. Biagi E., Dotti G., Yvon E., Lee E., Pule M., Vigouroux S., et al. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes. Blood 2005, 105:2436-2442.
16. Kater A.P., Evers L.M., Remmerswaal E.B., Jaspers A., Oosterwijk M.F., van Lier R.A., et al. CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. Br J Haematol 2004, 127:404-415.
17. Gricks C.S., Zahrieh D., Zauls A.J., Gorgun G., Drandi D., Mauerer K., et al. Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells. Blood 2004, 104:4002-4009.
18. McWhirter J.R., Kretz-Rommel A., Saven A., Maruyama T., Potter K.N., Mockridge C.I., et al. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci USA 2006, 103:1041-1046.
19. Gorczynski R.M., Lee L., Boudakov I. Augmented Induction of CD4+CD25+ Treg using monoclonal antibodies to CD200R. Transplantation 2005, 79:1180-1183.
20. Pallasch C.P., Ulbrich S., Brinker R., Hallek M., Uger R.A., Wendtner C.M. Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade. Leuk Res 2009, 33:460-464.
21. Fiorentino D.F., Bond M.W., Mosmann T.R. Two types of mouse T helper cell IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989, 170:2081-2095.
22. de Waal Malefyt R., Haanen J., Spits H., Roncarolo M.G., te Velde A., Figdor C., et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991, 174:915-924.
23. Fayad L., Keating M.J., Reuben J.M., O'Brien S., Lee B.N., Lerner S., et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 2001, 97:256-263.
24. Voorzanger N., Touitou R., Garcia E., Delecluse H.J., Rousset F., Joab I., et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 1996, 56:5499-5505.
25. Benjamin D., Knobloch T.J., Dayton M.A. Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10. Blood 1992, 80:1289-1298.
26. Fluckiger A.C., Durand I., Banchereau J. Interleukin 10 induces apoptotic cell death of B-chronic lymphocytic leukemia cells. J Exp Med 1994, 179:91-99.
27. Tangye S.G., Weston K.M., Raison R.L. Interleukin-10 inhibits the in vitro proliferation of human activated leukemic CD5+ B-cells. Leuk Lymphoma 1998, 31:121-130.
28. Kitabayashi A., Hirokawa M., Miura A.B. The role of interleukin-10 (IL-10) in chronic B-lymphocytic leukemia: IL-10 prevents leukemic cells from apoptotic cell death. Int J Hematol 1995, 62:99-106.
29. Reittie J.E., Yong K.L., Panayiotidis P., Hoffbrand A.V. Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukaemia. Leuk Lymphoma 1996, 22:83-90.
30. Aderka D., Maor Y., Novick D., Engelmann H., Kahn Y., Levo Y., et al. Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-alpha or -beta. Blood 1993, 81:2076-2084.
31. Buggins A.G., Patten P.E., Richards J., Thomas N.S., Mufti G.J., Devereux S. Tumor-derived IL-6 may contribute to the immunological defect in CLL. Leukemia 2008, 22:1084-1087.
32. Mainou-Fowler T., Proctor S.J., Miller S., Dickinson A.M. Expression and production of interleukin 4 in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2001, 42:689-698.
33. Mu X., Kay N.E., Gosland M.P., Jennings C.D. Analysis of blood T-cell cytokine expression in B-chronic lymphocytic leukaemia: evidence for increased levels of cytoplasmic IL-4 in resting and activated CD8 T cells. Br J Haematol 1997, 96:733-735.
34. Kay N.E., Han L., Bone N., Williams G. Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis. Br J Haematol 2001, 112:760-767.
35. Panayiotidis P., Ganeshaguru K., Jabbar S.A., Hoffbrand A.V. Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1993, 85:439-445.
36. Dancescu M., Rubio-Trujillo M., Biron G., Bron D., Delespesse G., Sarfati M. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992, 176:1319-1326.
37. de Totero D., Reato G., Mauro F., Cignetti A., Ferrini S., Guarini A., et al. IL4 production and increased CD30 expression by a unique CD8+ T-cell subset in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999, 104:589-599.
38. Cerutti A., Kim E.C., Shah S., Schattner E.J., Zan H., Schaffer A., et al. Dysregulation of CD30+ T cells by leukemia impairs isotype switching in normal B cells. Nat Immunol 2001, 2:150-156.
39. Lindqvist C.A., Christiansson L.H., Simonsson B., Enblad G., Olsson-Stromberg U., Loskog A.S. T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies. Immunology 2010, [Epub ahead of print].
40. Scrivener S., Goddard R.V., Kaminski E.R., Prentice A.G. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003, 44:383-389.
41. Matutes E., Wechsler A., Gomez R., Cherchi M., Catovsky D. Unusual T-cell phenotype in advanced B-chronic lymphocytic leukaemia. Br J Haematol 1981, 49:635-642.
42. Platsoucas C.D., Galinski M., Kempin S., Reich L., Clarkson B., Good R.A. Abnormal T lymphocyte subpopulations in patients with B cell chronic lymphocytic leukemia: an analysis by monoclonal antibodies. J Immunol 1982, 129:2305-2312.
43. Herrmann F., Lochner A., Philippen H., Jauer B., Ruhl H. Imbalance of T cell subpopulations in patients with chronic lymphocytic leukaemia of the B cell type. Clin Exp Immunol 1982, 49:157-162.
44. Tinhofer I., Marschitz I., Kos M., Henn T., Egle A., Villunger A., et al. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. Blood 1998, 91:4273-4281.
45. Pizzolo G., Chilosi M., Ambrosetti A., Semenzato G., Fiore-Donati L., Perona G. Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia. Blood 1983, 62:1289-1296.
46. Ghia P., Strola G., Granziero L., Geuna M., Guida G., Sallusto F., et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol 2002, 32:1403-1413.
47. Farace F., Orlanducci F., Dietrich P.Y., Gaudin C., Angevin E., Courtier M.H., et al. T cell repertoire in patients with B chronic lymphocytic leukemia Evidence for multiple in vivo T cell clonal expansions. J Immunol 1994, 153:4281-4290.
48. Rezvany M.R., Jeddi-Tehrani M., Osterborg A., Kimby E., Wigzell H., Mellstedt H. Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia: major perturbations are preferentially seen within the CD4 T-cell subset. Blood 1999, 94:1063-1069.
49. Goolsby C.L., Kuchnio M., Finn W.G., Peterson L. Expansions of clonal and oligoclonal T cells in B-cell chronic lymphocytic leukemia are primarily restricted to the CD3(+)CD8(+) T-cell population. Cytometry 2000, 42:188-195.
50. Baecher-Allan C., Viglietta V., Hafler D.A. Human CD4+CD25+ regulatory T cells. Semin Immunol 2004, 16:89-98.
51. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
52. Beyer M., Kochanek M., Darabi K., Popov A., Jensen M., Endl E., et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005, 106:2018-2025.
53. Giannopoulos K., Schmitt M., Kowal M., Wlasiuk P., Bojarska-Junak A., Chen J., et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 2008, 20:677-682.
54. Jak M., Mous R., Remmerswaal E.B.M., Spijker R., Jaspers A., Yague A., et al. Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia. Leuk Lymphoma 2009, 50:788-801.
55. Greenwald R.J., Freeman G.J., Sharpe A.H. The B7 family revisited. Annu Rev Immunol 2005, 23:515-548.
56. Motta M., Rassenti L., Shelvin B.J., Lerner S., Kipps T.J., Keating M.J., et al. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 2005, 19:1788-1793.
57. Gorgun G., Holderried T.A., Zahrieh D., Neuberg D., Gribben J.G. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 2005, 115:1797-1805.
58. Billadeau D.D., Nolz J.C., Gomez T.S. Regulation of T-cell activation by the cytoskeleton. Nat Rev Immunol 2007, 7:131-143.
59. Ramsay A.G., Johnson A.J., Lee A.M., Gorgun G., Le Dieu R., Blum W., et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008, 118:2427-2437.
60. Gorgun G., Ramsay A.G., Holderried T.A., Zahrieh D., Le Dieu R., Liu F., et al. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA 2009, 106:6250-6255.
61. Lauria F., Foa R., Mantovani V., Fierro M.T., Catovsky D., Tura S. T-cell functional abnormality in B-chronic lymphocytic leukaemia: evidence of a defect of the T-helper subset. Br J Haematol 1983, 54:277-283.
62. Chiorazzi N., Fu S.M., Montazeri G., Kunkel H.G., Rai K., Gee T. T cell helper defect in patients with chronic lymphocytic leukemia. J Immunol 1979, 122:1087-1090.
63. Richardson P.G., Schlossman R.L., Weller E., Hideshima T., Mitsiades C., Davies F., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100:3063-3067.
64. List A., Kurtin S., Roe D.J., Buresh A., Mahadevan D., Fuchs D., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352:549-557.
65. Weber D.M., Chen C., Niesvizky R., Wang M., Belch A., Stadtmauer E.A., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007, 357:2133-2142.
66. Chanan-Khan A., Miller K.C., Musial L., Lawrence D., Padmanabhan S., Takeshita K., et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006, 24:5343-5349.
67. Ferrajoli A., Lee B.N., Schlette E.J., O'Brien S.M., Gao H., Wen S., et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008, 111:5291-5297.
68. Aue G., Njuguna N., Tian X., Soto S., Hughes T., Vire B., et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica 2009, 94:1266-1273.
69. Andritsos L.A., Johnson A.J., Lozanski G., Blum W., Kefauver C., Awan F., et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008, 26:2519-2525.
70. Chanan-Khan A.A., Cheson B.D. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008, 26:1544-1552.
71. Wierda W.G., Cantwell M.J., Woods S.J., Rassenti L.Z., Prussak C.E., Kipps T.J. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000, 96:2917-2924.
72. Lapalombella R., Andritsos L., Liu Q., May S.E., Browning R., Pham L.V., et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B Cells through a PI3-kinase dependent pathway. Blood 2009, 115:2619-2629.
73. Badoux X., Reuben J., Lee B., Jorgensen J., Estrov Z., Yerrow K., et al. Lenalidomide therapy is associated with normalization of lymphocyte populations and increase in immunoglobulin levels in elderly patients with chronic lymphocytic leukemia. Haematologica 2009, 94. 10.31.
74. Corral L.G., Haslett P.A., Muller G.W., Chen R., Wong L.M., Ocampo C.J., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999, 163:380-386.
75. Xu Y., Li J., Ferguson G.D., Mercurio F., Khambatta G., Morrison L., et al. Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood 2009, 114:338-345.
76. Gaidarova S.L.J., Corral L.G., Glezer E., Schafer P.H., Xie W., Lopez-Girona A., et al. Lenalidomide alone and in combination with rituximab enhances NK cell immune synapse formation in chronic lymphocytic leukemia (CLL) cells in vitro through activation of Rho and Rac1 GTPases. Blood 2009, 114.
77. Gribben J.G. How I treat CLL up front. Blood 2010, 115:187-197.
78. Rai K.R., Peterson B.L., Appelbaum F.R., Kolitz J., Elias L., Shepherd L., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000, 343:1750-1757.
79. Hallek M., Fingerle-Rowson G., Fink A.M. Immunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression free survival (PFS) of previously untreated patients with advanced chronic lymphocytic leukemia (CLL). Blood 2008, 112. abstract 325.
80. Giannopoulos K., Dmoszynska A., Kowal M., Wasik-Szczepanek E., Bojarska-Junak A., Rolinski J., et al. Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia. Leukemia 2009, 23:1771-1778.
81. Ramsay A.G., Gribben J.G. Vaccine therapy and chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2008, 21:421-436.
82. Le Dieu R., Gribben J. Vaccine- and immune-based therapy in chronic lymphocytic leukemia. Semin Oncol 2006, 33:220-229.
83. Schmidt S.M., Schag K., Muller M.R., Weck M.M., Appel S., Kanz L., et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003, 102:571-576.
84. Giannopoulos K., Li L., Bojarska-Junak A., Rolinski J., Dmoszynska A., Hus I., et al. Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia. Int J Oncol 2006, 29:95-103.
85. Mayr C., Bund D., Schlee M., Bamberger M., Kofler D.M., Hallek M., et al. MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes. Exp Hematol 2006, 34:44-53.
86. Favaro P.M., de Souza Medina S., Traina F., Basseres D.S., Costa F.F., Saad S.T. Human leukocyte formin: a novel protein expressed in lymphoid malignancies and associated with Akt. Biochem Biophys Res Commun 2003, 311:365-371.
87. Mayr C., Bund D., Schlee M., Moosmann A., Kofler D.M., Hallek M., et al. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes. Blood 2005, 105:1566-1573.
88. Bund D., Mayr C., Kofler D.M., Hallek M., Wendtner C.M. CD23 is recognized as tumor-associated antigen (TAA) in B-CLL by CD8+ autologous T lymphocytes. Exp Hematol 2007, 35:920-930.
89. Fukuda T., Chen L., Endo T., Tang L., Lu D., Castro J.E., et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci USA 2008, 105:3047-3052.
90. Janeway C.A., Sakato N., Eisen H.N. Recognition of immunoglobulin idiotypes by thymus-derived lymphocytes. Proc Natl Acad Sci USA 1975, 72:2357-2360.
91. Trojan A., Schultze J.L., Witzens M., Vonderheide R.H., Ladetto M., Donovan J.W., et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 2000, 6:667-672.
92. Kwak L.W., Campbell M.J., Czerwinski D.K., Hart S., Miller R.A., Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992, 327:1209-1215.
93. Hsu F.J., Caspar C.B., Czerwinski D., Kwak L.W., Liles T.M., Syrengelas A., et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 1997, 89:3129-3135.
94. Harig S., Witzens M., Krackhardt A.M., Trojan A., Barrett P., Broderick R., et al. Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues. Blood 2001, 98:2999-3005.
95. Hus I., Rolinski J., Tabarkiewicz J., Wojas K., Bojarska-Junak A., Greiner J., et al. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia 2005, 19:1621-1627.
96. Hus I., Schmitt M., Tabarkiewicz J., Radej S., Wojas K., Bojarska-Junak A., et al. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response. Leukemia 2008, 22:1007-1017.
97. Spaner D.E., Hammond C., Mena J., Foden C., Deabreu A. A phase I/II trial of oxidized autologous tumor vaccines during the " watch and wait" phase of chronic lymphocytic leukemia. Cancer Immunol Immunother 2005, 54:635-646.
98. Palena C., Foon K.A., Panicali D., Yafal A.G., Chinsangaram J., Hodge J.W., et al. Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules. Blood 2005, 106:3515-3523.
99. Takahashi S., Yotnda P., Rousseau R.F., Mei Z., Smith S., Rill D., et al. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. Cancer Gene Ther 2001, 8:378-387.
100. Morgan R.A., Dudley M.E., Wunderlich J.R., Hughes M.S., Yang J.C., Sherry R.M., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129.
101. Kochenderfer J.N., Wilson W.H., Janik J.E., Dudley M.E., Stetler-Stevenson M., Feldman S.A., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically-engineered to recognize CD19. Blood 2010, [Epub ahead of print].
102. Hudecek M., Schmitt T.M., Baskar S., Lupo-Stanghellini M.T., Nishida T., Yamamoto T.N., et al. The B-cell tumor associated antigen ROR1 can be targeted with T-cells modified to express a ROR1-specific chimeric antigen receptor. Blood 2010, [Epub ahead of print].
103. James S.E., Orgun N.N., Tedder T.F., Shlomchik M.J., Jensen M.C., Lin Y., et al. Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice. Blood 2009, 114:5454-5463.
104. Schetelig J., Thiede C., Bornhauser M., Schwerdtfeger R., Kiehl M., Beyer J., et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol: Off J Am Soc Clin Oncol 2003, 21:2747-2753.
105. Dreger P., Brand R., Milligan D., Corradini P., Finke J., Lambertenghi Deliliers G., et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leuk: Off J Leuk Soc Am 2005, 19:1029-1033. [Leukemia Research Fund, UK].
106. Gribben J.G., Zahrieh D., Stephans K., Bartlett-Pandite L., Alyea E.P., Fisher D.C., et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005, 106:4389-4396.
107. Caballero D., Garcia-Marco J.A., Martino R., Mateos V., Ribera J.M., Sarra J., et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res: Off J Am Assoc Cancer Res 2005, 11:7757-7763.
108. Kater A.P., van Oers M.H., Kipps T.J. Cellular immune therapy for chronic lymphocytic leukemia. Blood 2007, 110:2811-2818.
109. Zenz T., Ritgen M., Dreger P., Krober A., Barth T.F., Schlenk R., et al. Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 2006, 108:2127-2130.